Nektar Therapeutics APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Nektar Therapeutics (NKTR) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $3.37 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-14
- Nektar Therapeutics apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $3.37M, a 3.47% decline year-over-year.
- Nektar Therapeutics apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $3.35M, a 13.93% decline year-over-year.
- Nektar Therapeutics apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.07M, a 43.02% decline year-over-year.
- Nektar Therapeutics apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $3.49M, a 35.66% decline year-over-year.
- Nektar Therapeutics apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $12.65M, a 41.47% decline from fiscal 2024.
- Nektar Therapeutics apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $21.61M, a 35.27% decline from fiscal 2023.
- Nektar Therapeutics apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $33.39M, a 41.75% decline from fiscal 2022.
- Nektar Therapeutics apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $57.32M, a 39.46% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.37M 10-Q · filed 2026-08-14 | $6.72M derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $3.35M 10-Q · filed 2026-08-14 | |||
| 2025-12-31 | $12.65M 10-K · filed 2026-03-13 | |||
| 2025-09-30 | $3.07M 10-Q · filed 2025-11-07 | $6.56M derived: sum of 2 quarters · filed 2026-08-14 | $10.46M derived: sum of 3 quarters · filed 2026-08-14 | |
| 2025-06-30 | $3.49M 10-Q · filed 2026-08-14 | $7.38M derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $3.90M 10-Q · filed 2026-08-14 | |||
| 2024-12-31 | $21.61M 10-K · filed 2026-03-13 | |||
| 2024-09-30 | $5.39M 10-Q · filed 2025-11-07 | $10.81M derived: sum of 2 quarters · filed 2025-11-07 | $16.81M derived: sum of 3 quarters · filed 2025-11-07 | |
| 2024-06-30 | $5.42M 10-Q · filed 2025-11-07 | $11.42M derived: sum of 2 quarters · filed 2025-11-07 | ||
| 2024-03-31 | $6.00M 10-Q · filed 2025-11-07 | |||
| 2023-12-31 | $33.39M 10-K · filed 2025-03-14 | |||
| 2023-09-30 | $8.15M 10-Q · filed 2024-11-08 | $16.11M derived: sum of 2 quarters · filed 2024-11-08 | $26.13M derived: sum of 3 quarters · filed 2024-11-08 | |
| 2023-06-30 | $7.97M 10-Q · filed 2024-11-08 | $17.98M derived: sum of 2 quarters · filed 2024-11-08 | ||
| 2023-03-31 | $10.02M 10-Q · filed 2024-11-08 | |||
| 2022-12-31 | $57.32M 10-K · filed 2024-03-05 | |||
| 2022-09-30 | $12.52M 10-Q · filed 2023-11-08 | $23.62M derived: sum of 2 quarters · filed 2023-11-08 | $44.58M derived: sum of 3 quarters · filed 2023-11-08 | |
| 2022-06-30 | $11.10M 10-Q · filed 2023-11-08 | $32.06M derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2022-03-31 | $20.96M 10-Q · filed 2023-11-08 | |||
| 2021-12-31 | $94.67M 10-K · filed 2024-03-05 | |||
| 2021-09-30 | $24.66M 10-Q · filed 2022-11-04 | $48.37M derived: sum of 2 quarters · filed 2022-11-04 | $72.27M derived: sum of 3 quarters · filed 2022-11-04 | |
| 2021-06-30 | $23.71M 10-Q · filed 2022-11-04 | $47.61M derived: sum of 2 quarters · filed 2022-11-04 | ||
| 2021-03-31 | $23.90M 10-Q · filed 2022-11-04 | |||
| 2020-12-31 | $94.26M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $23.67M 10-Q · filed 2021-11-05 | $48.06M derived: sum of 2 quarters · filed 2021-11-05 | $72.27M derived: sum of 3 quarters · filed 2021-11-05 | |
| 2020-06-30 | $24.40M 10-Q · filed 2021-11-05 | $48.61M derived: sum of 2 quarters · filed 2021-11-05 | ||
| 2020-03-31 | $24.21M 10-Q · filed 2021-11-05 | |||
| 2019-12-31 | $99.80M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $24.88M 10-Q · filed 2020-11-06 | $49.40M derived: sum of 2 quarters · filed 2020-11-06 | $74.79M derived: sum of 3 quarters · filed 2020-11-06 | |
| 2019-06-30 | $24.52M 10-Q · filed 2020-11-06 | $49.91M derived: sum of 2 quarters · filed 2020-11-06 | ||
| 2019-03-31 | $25.39M 10-Q · filed 2020-11-06 | |||
| 2018-12-31 | $88.10M 10-K · filed 2021-02-26 | |||
| 2018-09-30 | $23.29M 10-Q · filed 2019-11-07 | $43.95M derived: sum of 2 quarters · filed 2019-11-07 | $63.90M derived: sum of 3 quarters · filed 2019-11-07 | |
| 2018-06-30 | $20.66M 10-Q · filed 2019-11-07 | $40.61M derived: sum of 2 quarters · filed 2019-11-07 | ||
| 2018-03-31 | $19.95M 10-Q · filed 2019-11-07 | |||
| 2017-12-31 | $36.62M 10-K · filed 2020-02-28 | |||
| 2016-12-31 | $25.85M 10-K · filed 2019-03-01 | |||
| 2015-12-31 | $19.67M 10-K · filed 2018-03-01 | |||
| 2014-12-31 | $17.02M 10-K · filed 2017-03-01 | |||
| 2013-12-31 | $17.71M 10-K · filed 2016-02-29 | |||
| 2012-12-31 | $16.20M 10-K · filed 2015-02-26 | |||
| 2011-12-31 | $18.89M 10-K · filed 2014-02-27 | |||
| 2010-12-31 | $17.40M 10-K · filed 2013-03-01 | |||
| 2009-12-31 | $10.33M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |